GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
85 articles in GLP-1 & Metabolic · page 4 of 8
Tolerance to GLP-1s: Does It Happen?
Does the body adapt and the weight effect fade? What multi-year semaglutide and tirzepatide trials actually show.
Read →GLP-1s and Insurance Coverage in 2026
Medicare's weight-loss exclusion, the temporary GLP-1 Bridge, 13 Medicaid states, and employer variation — the documented coverage picture, with dates.
Read →The History of Incretin Research, Briefly
From secretin in 1902 to tirzepatide in 2022: the verified dates and names behind the incretin story, and the long gaps between them.
Read →GLP-1s and Appetite Hormones: Leptin and Ghrelin
How GLP-1 drugs interact with the body's other hunger signals.
Read →How GLP-1s Slow Gastric Emptying
The mechanism behind both the fullness and the nausea — and why it fades over time.
Read →GLP-1s and Eating Disorders: A Cautious Look
Appetite effects demand particular care. What the limited eating-disorder evidence shows.
Read →Why GLP-1 Trials Use Different Endpoints
Weight, A1c, cardiovascular events: what a GLP-1 trial measures shapes what its result can honestly claim.
Read →GLP-1s in Adolescents: The Evidence and the Debate
In STEP TEENS, semaglutide cut BMI ~16% over 68 weeks. Efficacy is clear; long-term safety in growing bodies isn't.
Read →The Durability Question: GLP-1s as Chronic Therapy
These look more like blood-pressure drugs than a course of antibiotics. Why that framing matters.
Read →Amylin and the Next Wave: CagriSema, Explained
CagriSema cut weight ~20% in REDEFINE 1 (NEJM 2025). The amylin-plus-GLP-1 strategy, in context.
Read →GLP-1s and Blood Pressure: What the Trials Found
A modest but consistent effect that adds to the cardiometabolic case.
Read →GLP-1s and Cholesterol: Secondary Metabolic Effects
Weight isn't the only marker that moves. What the lipid data from semaglutide trials shows.
Read →